Lv1
20 积分 2025-03-18 加入
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
17小时前
已完结
Outcomes Among Adult Recipients of CAR T-cell Therapy for Burkitt Lymphoma
11天前
已完结
Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma
13天前
已完结
A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains
14天前
已完结
Site-specific analysis of extranodal involvement in large B-cell lymphoma reveals distinct efficacy with chimeric antigen receptor T-cell therapy
15天前
已完结
Role of bridging RT in relapsed/refractory diffuse large B-cell lymphoma undergoing CAR-T therapy: a multicenter study
15天前
已完结
Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma
15天前
已完结
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
20天前
已完结
DLBCL: Who is high risk and how should treatment be optimized?
21天前
已完结
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study
27天前
已完结
皖公网安备34019202002308
